LMT-28
LMT-28 性质
| 沸点 | 452.9±38.0 °C(Predicted) |
|---|---|
| 密度 | 1.065±0.06 g/cm3(Predicted) |
| 储存条件 | -20°C |
| 溶解度 | 100 mg/mL 的 DMSO (321.11 mM) 溶液， |
| 酸度系数(pKa) | 13.97±0.20(Predicted) |
| 形态 | 油状 |
| 颜色 | 无色至淡黄色 |
| 水溶解性 | < 0.1 mg/mL Water (insoluble) |
| InChI | 1S/C17H29NO4/c1-6-7-8-9-12(4)15(19)13(5)16(20)18-14(11(2)3)10-22-17(18)21/h11,13-15,19H,4,6-10H2,1-3,5H3/t13-,14+,15+/m0/s1 |
| InChIKey | UDXWSYOXIRPYFK-RRFJBIMHSA-N |
| SMILES | CC(C)[C@H](N1C([C@@H](C)[C@H](O)C(CCCCC)=C)=O)COC1=O |
LMT-28 用途与合成方法
|
IL-6
|
LMT-28 reduces IL-6-induced luciferase activity by ~90% at a concentration of 50 μM and exhibits an IC
50
value of 5.9 μM. LMT-28 (1-10 μM; 72 hours) inhibits IL-6-induced proliferation of the human erythroleukemic cell line TF-1.
LMT-28 (1-100 μM; 1 hour) selectively inhibits IL-6-induced phosphorylation of STAT3, JAK2, and gp130.
Cell Proliferation Assay
| Cell Line: | TF-1 cells (1 ng/mL IL-6-induced) |
| Concentration: | 1, 10, 100, 1000, 10000 nM |
| Incubation Time: | 72 hours |
| Result: | Markedly inhibited IL-6–induced TF-1 proliferation with an IC50 value of 7.5 μM. |
Western Blot Analysis
| Cell Line: | HepG2 cells (treated with 10 ng/mL IL-6) |
| Concentration: | 1, 3, 10, 30, and 100 μM |
| Incubation Time: | 1 hour |
| Result: | Inhibits IL-6-induced phosphorylation of STAT3, JAK2, and gp130. |
LMT-28 (0-0.5 mg/kg; p.o.; once daily for 15 days) alleviates CIA in mice.
LMT-28 (0.25 or 1 mg/kg; p.o.) ameliorates the progression of pancreatitis in mice. LMT-28 binds directly and specifically to gp130, and thereby inhibits the interaction of gp130 with the IL-6/IL-6Rα complex.
| Animal Model: | Six-week-old male DBA/1J mice (collagen-induced arthritis mice, CIA) |
| Dosage: | 0-0.5 mg/kg |
| Administration: | Oral; once daily for 15 days |
| Result: | Markedly reduced the serum levels of cartilage oligomeric matrix protein (COMP) by 50%, serum amyloid P (SAP) by 55%, and anti-CII IgG by 62%. |
LMT-28 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-09-15 | HY-102084 | 1239600-18-0 | 1 mg | 320 | |
| 2026-09-15 | HY-102084 | LMT-28 | 1239600-18-0 | 5mg | 730 |
